STOCK TITAN

Baxter Intl (BAX) Stock News

BAX NYSE

Welcome to our dedicated page for Baxter Intl news (Ticker: BAX), a resource for investors and traders seeking the latest updates and insights on Baxter Intl stock.

Baxter International Inc. reports news on its global medtech business, which supplies hospitals, physician offices and other care settings with connected solutions, medical devices and advanced injectable technologies. Company updates commonly cover results from continuing operations following the Kidney Care divestiture, portfolio activity in infusion therapies and platforms, surgical tables, smart stretchers, patient-support systems, monitoring tools, and hemostatic and sealing agents.

Baxter announcements also address product introductions such as the IV Verify Line Labeling System, conference showcases for Global Surgical Solutions, Advanced Surgery and Patient Support Systems, annual-meeting matters, executive finance leadership, and foundation partnerships tied to healthcare settings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
conferences earnings date
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.85%
Tags
conferences
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
-
News
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.55%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
none
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.68%
Tags
none
-
News
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.78%
Tags
dividends
-
Rhea-AI Summary

Baxter International Inc. (NYSE:BAX) reported first-quarter 2023 revenue of $3.65 billion, a 2% decrease year-over-year on a reported basis but a 2% increase on a constant currency basis. U.S. GAAP earnings per share (EPS) were $0.09, while adjusted EPS was $0.59. For 2023, Baxter anticipates sales growth of 1% to 2% and U.S. GAAP EPS between $1.16 and $1.31, with adjusted EPS between $2.85 and $3.00. Key drivers for sales included Advanced Surgery and Pharmaceuticals, though declines were noted in Acute Therapies and Patient Support Systems. The company is also advancing a strategic spinoff of its Kidney Care segment, expected to occur by July 2024. Innovation efforts include launching the Novum IQ and ExactaMix Pro systems, aimed at enhancing patient care and operational efficiency.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
Rhea-AI Summary

Baxter International Inc. (NYSE:BAX) will present at the BofA Securities 2023 Health Care Conference on May 9, 2023. Chief Financial Officer Jay Saccaro is scheduled to speak at 1:00 p.m. Eastern Time. A live webcast of the presentation can be accessed on www.baxter.com and will remain available for replay until November 5, 2023.

Baxter provides critical care, kidney care, and surgical products that are vital for patients and caregivers in over 100 countries. With a history spanning more than 90 years, the company continues to innovate in healthcare solutions, enhancing patient care and supporting providers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags
conferences

FAQ

What is the current stock price of Baxter Intl (BAX)?

The current stock price of Baxter Intl (BAX) is $26.41 as of August 20, 2026.

What is the market cap of Baxter Intl (BAX)?

The market cap of Baxter Intl (BAX) is approximately 13.7B.